Faron Pharmaceuticals Oy (LSE:FARN) Short Interest


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.41
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LSE:FARN vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Short Interest distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Short Interest falls into.


LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41
Price